Read this company snapshot
Daily valuation snapshot
Erasca, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $16.03
- Market capitalization (USD)
- $5,606,685,421.05
- Price / earnings (TTM)
- Not reported
- Price / book
- 15.49
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ERAS in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ERAS in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing ERAS with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $16.03 |
| Market capitalization (USD) | $5,606,685,421.05 |
| Price / earnings (TTM) | Not reported |
| Price / book | 15.49 |
No matching rows. Clear the filter to see all records.
Read ERAS's valuation metrics
Company size
Erasca, Inc. Common Stock's recorded market capitalization is $5,606,685,421.05. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
ERAS's recorded price-to-book ratio is 15.49. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Erasca, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about ERAS. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow ERAS's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.